Treatment strategies for diabetic patients suffering from erectile dysfunction: An update

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 13, 2014, Pages 1827-1836

  Redrow, Grant P ^a   Thompson, Chad M ^a   Wang, Run ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Diabetes; Erectile dysfunction; PDE5 inhibitor; Review; Treatment

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR;

CLINICAL TRIAL (TOPIC); DIABETES COMPLICATIONS; ERECTILE DYSFUNCTION; HUMAN; MALE; PENIS PROSTHESIS; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; DIABETES COMPLICATIONS; ERECTILE DYSFUNCTION; HUMANS; MALE; PENILE PROSTHESIS; PHOSPHODIESTERASE 5 INHIBITORS; TREATMENT OUTCOME;

EID: 84905821185     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.934809     Document Type: Review

References (104)

1. Thorve VS, Kshirsagar AD, Vyawahare NS, et al. Diabetes-induced erectile dysfunction: epidemiology, pathophysiology and management. J Diabetes Complications 2011;25(2):129-36
2. Penson DF, Latini DM, Lubeck DP, et al. Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database. Diabetes Care 2003;26:1093-9
3. De Berardis G, Franciosi M, Belfigilo M, et al. Erectile dysfunction and quality of life in type 2 diabetic patients a serious problem too often overlooked. Diabetes Care 2002;25(2):284-91
4. Avasthi A, Grover S, Bhansali A, et al. Erectile dysfunction in diabetes mellitus contributes to poor quality of life. Int Rev Psychiatry 2011;23(1):93-9
5. Lu CC, Jian BP, Sun CC, et al. Association of glycemic control with risk of erectile dysfunction in men with type 2 diabetes. J Sex Med 2009;6(6):1719-28
6. Yaman O, Akand M, Erdogan MF, et al. The effect of diabetes mellitus treatment and good glycemic control on the erectile function in men with diabetes mellitusinduced erectile dysfunction: a pilot study. J Sex Med 2006;3(2):344-8
7. Gupta BP, Murad HM, Clifton MM, et al. The Effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction a systematic review and meta-analysis. Arch Intern Med 2011;171(20):1797-803
8. Wing RR, Rosen RC, Fava JL, et al. Effects of weight loss intervention on erectile function in older men with type 2 diabetes in the Look AHEAD trial. J Sex Med 2010;7(1):156-65
9. Cartledge JJ, Eardley I, Morrison JF. Advanced glycation end-products are responsible for the impairment of corpus cavernosal smooth muscle relaxation seen in diabetes. BJU Int 2001;87:402-7
10. Cellek S, Rodrigo J, Lobos E, et al. Selective nitrergic neurodegeneration in diabetes mellitus-A nitric oxidedependent phenomenon. Br J Pharmacol 1999;128(8):1804-12
11. Vernet D, Cai L, Garban H, et al. Reduction of penile nitric oxide synthase in diabetic BB/WORdp (type I) and BBZ/WORdp (type II) rats with erectile dysfunction. Endocrinology 1995;136(12):5709-17
12. Kapoor D, Aldred H, Clark S, et al. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007;30(4):911-17
13. Mikhail N. Does testosterone have a role in erectile functioñ Am J Med 2006;119(5):373-82
14. Hatzimouratidis K, Hatzichristou D. Erectile dysfunction and diabetes mellitus. Insulin 2009;4(2):114-22
15. Thorve VS, Kshirsagar AD, Vyawahare NS, et al. Diabetes-induced erectile dysfunction: epidemiology, pathophysiology and management. J Diabetes Complications 2011;25(2):129-36
16. Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. J Sex Med 2009;6(5):1232-47
17. Gandaglia G, Briganti A, Jackson G, et al. A systematic review of the association between erectile dysfunction and cardiovascular disease. Eur Urol 2014;65(5):968-78
18. Levine GN, Steinke EE, Bakaeen FG, et al. Sexual activity and cardiovascular disease a scientific statement from the American Heart Association. Circulation 2012;125(8):1058-72
19. Hatzimouratidis K, Amar E, Eardley I, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010
20. Hackett G, Kell P, Ralph D, et al. British society for sexual medicine guidelines on the management of erectile dysfunction. J Sex Med 2008;5(8):1841-65
21. Porst H, Burnett A, Brock G, et al. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med 2013;10(1):130-71
22. Nehra A, Jackson G, Miner M, et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc 2012;87(8):766-78
23. Fonseca V, Jawa A. Endothelial and erectile dysfunction, diabetes mellitus, and the metabolic syndrome: common pathways and treatments? Am J Cardiol 2005;96(12):13-18
24. El-Sakka AI, Sayed HM, Tayeb KA. Androgen pattern in patients with type 2 diabetes-associated erectile dysfunction: impact of metabolic control. Urology 2009;74(3):552-9
25. Trivedi D, Kirby M, Norman F, et al. Can simvastatin improve erectile function and health-related quality of life in men aged ? 40 years with erectile dysfunctioñ Results of the Erectile Dysfunction and Statins Trial [ISRCTN66772971]. BJU Int 2013;111(2):324-33
26. Kostis JB, Dobrzynski JM. The effect of statins on erectile dysfunction: a metaanalysis of randomized trials. J Sex Med 2014. [Epub ahead of print]
27. Nicolai MPJ, Liem SS, Pelger RCM, et al. A review of the positive and negative effects of cardiovascular drugs on sexual function: a proposed table for use in clinical practice Netherlands. Heart J 2014;22(1):11-19
28. Caro JLL, Vidal L, Aznar VJ, et al. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci 2001;321(5):336-41
29. Fogari R, Zoppi A, Poletti L, et al. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens 2001;14(1):27-31
30. Baumhäkel MN, Schlimmer N, Böhm M. Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome. Int J Impot Res 2008;20(5):493-500
31. Chen Y, Cui S, Lin H, et al. Losartan improves erectile dysfunction in diabetic patients: a clinical trial. Int J Impot Res 2012;24(6):217-20
32. Nieschlag E, Swerdloff R, Behre HM, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations. Eur Urol 2005;48(1):1-4
33. Kapoor D, Aldred H, Clark S, et al. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007;30(4):911-17
34. Ghazi S, Zohdy W, El Khiat Y, Shamloul R. Serum testosterone levels in diabetic men with and without erectile dysfunction. Andrologia 2012;44(6):373-80
35. Hackett G, Cole N, Bhartia M, et al. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. J Sex Med 2013;10(6):1612-27
36. Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011;34(4):828-37
37. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med 2010;363(2):109-22
38. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med 2013;11:108
39. Muraleedharan V, Marsh H, Kapoor D, et al. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol 2013;169(6):725-33
40. Seal LJ. Male hypogonadism and testosterone replacement therapy. Medicine 2013;41(10):557-61
41. Goldstein I, Jones LA, Belkoff LH, et al. Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus. Mayo Clin Proc 2012;87(9):843-52. Elsevier
42. Moon DG, Yang DY, Lee CH, et al. A Therapeutic confirmatory study to assess the safety and efficacy of Zydena (Udenafil) for the treatment of erectile dysfunction in male patients with diabetes mellitus. J Sex Med 2011;8(7):2048-61
43. Lee J, Yoo HH, Rhim KJ, et al. Metabolism and excretion of 5-ethyl-2-{5-[4-(2-hydroxyethyl) piperazine-1-sulfonyl]-2-propoxyphenyl}-7- propyl-3, 5-dihydropyrrolo [3, 2-d]-pyrimidin-4-one (SK3530) in rats. Rapid Commun Mass Spectrom 2007;21(7):1139-49
44. Deyoung L, Chung E, Kovac JR, et al. Daily use of sildenafil improves endothelial function in men with type 2 diabetes. J Androl 2012;33(2):176-80
45. Hatzichristou D, Gambla M, Rubio-Aurioles E, et al. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet Med 2008;25(2):138-46
46. Egerdie RB, Auerbach S, Roehrborn CG, et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med 2012;9(1):271-81
47. Price DE, Gingell JC, Gepi-Attee S, et al. Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men. Diabet Med 1998;15(10):821-5
48. Israilov S, Shmuely J, Niv E, et al. Evaluation of a progressive treatment program for erectile dysfunction in patients with diabetes mellitus. Int J Impot Res 2005;17(5):431-6
49. Behrend L, Vibe-Petersen J, Perrild H. Sildenafil in the treatment of erectile dysfunction in men with diabetes: demand, efficacy and patient satisfaction. Int J Impot Res 2005;17(3):264-9
50. Safarinejad MR. Oral sildenafil in the treatment of erectile dysfunction in diabetic men: a randomized double-blind and placebo-controlled study. J Diabetes Complications 2004;18(4):205-10
51. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. JAMA 1999;281(5):421-6
52. Blonde L. Sildenafil citrate for erectile dysfunction in men with diabetes and cardiovascular risk factors: a retrospective analysis of pooled data from placebocontrolled trials. Curr Med Res Opin 2006;22(11):2111-20
53. Boulton AJM, Selam JL, Sweeney M, Ziegler D. Sildenafil citrate for the treatment of erectile dysfunction in men with type II diabetes mellitus. Diabetologia 2001;44(10):1296-301
54. El-Sakka AI. Efficacy of sildenafil citrate in treatment of erectile dysfunction: effect of type 2 diabetes. Eur Urol 2004;46(4):503-9
55. Cui Y, Zong H, Yan H, Zhang Y. The effect of statins on erectile dysfunction: a systematic review and meta-analysis. J Sex Med 2014;11(6):1367-75
56. Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes a multicenter double-blind placebocontrolled fixed-dose study. Diabetes Care 2003;26(3):777-83
57. Ishii N, Nagao K, Fujikawa K, et al. Vardenafil 20-mg demonstrated superior efficacy to 10-mg in Japanese men with diabetes mellitus suffering from erectile dysfunction. Int J Urol 2006;13(8):1066-72
58. Ziegler D, Merfort F, Van Ahlen H, et al. Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. J Sex Med 2006;3(5):883-91
59. Buvat J, Ahlen HV, Schmitt H, et al. Efficacy and safety of two dosing regimens of tadalafil and patterns of sexual activity in men with diabetes mellitus and erectile dysfunction: scheduled use vs. on-demand regimen evaluation (SURE) study in 14 European countries. J Sex Med 2006;3(3):512-20
60. Fonseca V, Seftel A, Denne J, Fredlund P. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. Diabetologia 2004;47(11):1914-23
61. Kyle JA, Brown DA, Hill JK. Avanafil for erectile dysfunction. Ann Pharmacother 2013;47(10):1312-20
62. Kang KK, Choi SM, Ahn GJ, et al. The effect of DA-8159 on corpus cavernosal smooth muscle relaxation and penile erection in diabetic rabbits. Urol Res 2004;32(2):107-11
63. Ahn GJ, Sohn YS, Kang KK, et al. The effect of PDE5 inhibition on the erectile function in streptozotocin-induced diabetic rats. Int J Impot Res 2005;17(2):134-41
64. Yu JY, Kang KK, Yoo M, Kwon JW. Penile erectile responses to electric stimulation are enhanced by a new phosphodiesterase type-5 inhibitor. Int J Urol 2005;12(3):299-304
65. A.hn GJ, Yu JY, Choi SM, et al. Chronic administration of phosphodiesterase 5 inhibitor improves erectile and endothelial function in a rat model of diabetes. Int J Androl 2005;28(5):260-6
66. Ding H, Du W, Zhang L, et al. Efficacy and safety of udenafil for erectile dysfunction: a meta-analysis of randomized controlled trials. Urology 2012;80(1):134-9
67. Park HJ, Choi HK, Park JK, et al. Efficacy and safety of oral mirodenafil in the treatment of erectile dysfunction in diabetic men in Korea: a multicenter, randomized, double-blind, placebocontrolled clinical trial. J Sex Med 2010;7(8):2842-50
68. Hackett G. PDE5 inhibitors in diabetic peripheral neuropathy. Int J Clin Pract 2006;60(9):1123-6
69. Hamidi MA, Asadolahzade A, Mokhtari G, et al. Assessment of the efficacy of combination therapy with folic acid and tadalafil for the management of erectile dysfunction in men with type 2 diabetes mellitus. J Sex Med 2013;10(4):1146-50
70. Cui H, Liu B, Song Z, et al. Efficacy and safety of long-term tadalafil 5 mg once daily combined with sildenafil 50 mg as needed at the early stage of treatment for patients with erectile dysfunction. Andrologia 2014. [Epub ahead of print]
71. Canguven O, Bailen J, Fredriksson W, et al. Combination of vacuum erection device and PDE5 inhibitors as salvage therapy in PDE5 inhibitor nonresponders with erectile dysfunction. J Sex Med 2009;6:2561-7
72. Lin HC, Yang WL, Zhang JL, Wang R. Penile rehabilitation with a vacuum erectile device in an animal model is related to an antihypoxic mechanism: blood gas evidence. Asian J Androl 2013;15:387-90
73. Dhir R, Lin HC, Canfield S, Wang R. Combination therapy for erectile dysfunction: an update review. Asian J Androl 2011;13(3):382-90
74. Bancroft J, Gutierrez P. Erectile dysfunction in men with and without diabetes mellitus: a comparative study. Diabet Med 1996;13:84-9
75. Virag R. Intracavernous injection of papaverine for erectile failure. Lancet 1982;2:938
76. Perimenis P, Konstantinopoulos A, Perimeni PP, et al. Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction. Asian J Androl 2006;8(2):219-24
77. Althof SE, Turner LA, Levine SB, et al. Why do so many people drop out from auto-injection therapy for impotence? J Sex Marital Ther 1989;15:121-9
78. Coombs PG, Heck M, Guhring P, et al. A review of outcomes of an intracavernosal injection therapy programme. BJU Int 2012;110(11):1787-91
79. Perimenis P, Gyftopoulos K, Athanasopoulos A, et al. Diabetic impotence treated by intracavernosal injections: high treatment compliance and increasing dosage of vaso-active drugs. Eur Urol 2001;40:398-403
80. Padma-Nathan H, Hellstrom WJG, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med 1997;336:1-7
81. Li MK, Lim PH, Wong MY, et al. Transurethral alprostadil for the treatment of erectile dysfunction: results of a multicentre trial. Ann Acad Med Singapore 2000;29:727-31
82. Hanchanale V, Eardley I. Alprostadil in the treatment of impotence. Expert Opin Pharmacother 2014;15(3):421-8
83. Costa P, Potempa AJ. Intraurethral alprostadil for erectile dysfunction a review of the literature. Drugs 2012;72(17):2243-54
84. Kayigil O, Okulu E, Aldemir M, Onen E. Penile revascularization in vasculogenic erectile dysfunction (ED): long-term follow-up. BJU Int 2012;109(1):109-15
85. Dicks B, Bastuba M, Goldstein I. Penile revascularization-contemporary update. Asian J Androl 2013;15(1):5-9
86. Chung E, Van CT, Wilson I, Cartmill RA. Penile prosthesis implantation for the treatment for male erectile dysfunction: clinical outcomes and lessons learnt after 955 procedures. World J Urol 2013;31(3):591-5
87. Montague DK, Angermeier KW, Lakin MM. Penile prosthesis infections. Int J Impot Res 2001;13:326-8
88. Mulcahy JJ, Carson CC III. Long-term infection rates in diabetic patients implanted with antibiotic-impregnated versus nonimpregnated inflatable penile prostheses: 7-year outcomes. Eur Urol 2011;60:167-72
89. Hellstrom WJG, Drogo K, Montague MD, et al. Implants, mechanical devices, and vascular surgery for erectile dysfunction. J Sex Med 2010;7(1):501-23
90. Vardi Y, Appel B, Kilchevsky A, Gruenwald I. Does low intensity extracorporeal shock wave therapy have a physiological effect on erectile functioñ Short-term results of a randomized, double-blind, sham controlled study. J Urol 2012;187(5):1769-75
91. Gruenwald I, Appel B, Vardi Y. Low-intensity extracorporeal shock wave therapy-A novel effective treatment for erectile dysfunction in severe ED patients who respond poorly to PDE5 inhibitor therapy. J Sex Med 2012;9(1):259-64
92. Vardi Y, Appel B, Jacob G, et al. Can low-intensity extracorporeal shockwave therapy improve erectile functioñ A 6-month follow-up pilot study in patients with organic erectile dysfunction. Eur Urol 2010;58(2):243-8
93. Qiu X, Lin G, Xin Z, et al. Effects of low-energy shockwave therapy on the erectile function and tissue of a diabetic rat model. J Sex Med 2013;10(3):738-46
94. Liu J, Zhou F, Li GY, et al. Evaluation of the effect of different doses of low energy shock wave therapy on the erectile function of streptozotocin (STZ)-induced diabetic rats. Int J Mol Sci 2013;14(5):10661-73
95. Qiu X, Lin H, Wang Y, et al. Intracavernous transplantation of bone marrow-derived mesenchymal stem cells restores erectile function of streptozocininduced diabetic rats. J Sex Med 2011;8(2):427-36
96. Garcia MM, Fandel TM, Lin G, et al. Treatment of erectile dysfunction in the obese type 2 diabetic ZDF rat with adipose tissue-derived stem cells. J Sex Med 2010;7(1 pt 1):89-98
97. Bertolini A, Gessa GL. Behavioral effects of ACTH and MSH peptides. J Endocrinol Invest 1980;4(2):241-51
98. Diamond LE, Earle DC, Rosen RC, et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 2004;16(1):51-9
99. Dula E, Bukofzer S, Perdok R, George M. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol 2001;39(5):558-64
100. Padma-Nathan H, Steidle C, Salem S, et al. The efficacy and safety of a topical alprostadil cream, Alprox-TD, for the treatment of erectile dysfunction: two phase 2 studies in mild-to-moderate and severe ED. Int J Impot Res 2003;15(1):10-17
101. Abdel-Hamid IA, Andersson KE, Salonia A. Exploration of therapeutic targets for sexual dysfunctions: lessons learned from the failed stories. Expert Opin Ther Targets 2011;15(3):325-40
102. Lin H, Yuan J, Ruan KH, et al. COX-2-10aa-PGIS gene therapy improves erectile function in rats after cavernous nerve injury. J Sex Med 2013;10:1476-87
103. Melman A, Bar-Chama N, McCullough A, et al. The first human trial for gene transfer therapy for the treatment of erectile dysfunction: preliminary results. Eur Urol 2005;48(2):314-18
104. Melman A, Bar-Chama N, McCullough A, et al. hMaxi-K gene transfer in males with erectile dysfunction: results of the first human trial. Hum Gene Ther 2006;17(12):1165-17